Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca to analyse data from failed phase III trial

AstraZeneca to analyse data from failed phase III trial

25th February 2009

AstraZeneca will work with partner MAP Pharmaceuticals to analyse data from a phase III clinical trial of a drug intended to treat children’s asthma that has not achieve the desired results.

The investigation of Unit Dose Budesonide (UDB) was measured by changes from baseline in night and daytime symptom scores for the respiratory problem in youngsters.

It was found not to meet its targets in either of the doses trialled against a placebo.

Together, the two companies have an agreement to develop and commercialise the treatment.

MAP Pharmaceuticals concentrates on creating new therapies for children and adults who suffer from chronic conditions that can not be controlled adequately with drugs currently available to them on the market.

As well as examining UDB in a phase III trial, the firm is also analysing MAP0004 at the same stage of research. The latter medication is being developed for the potential remedy of migraines.

One of the largest pharmaceutical companies in the world, AstraZeneca specialises in cardiovascular, respiratory, gastrointestinal, neuroscience, oncology and infectious disease medicines.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.